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Objective:The use of endovascular techniques to treat renal artery stenosis (RAS) has increased in recent years but remains
controversial. The purpose of this study was to review the outcomes and durability of percutaneous transluminal
angioplasty and stenting (PTA/S) for patients with RAS and decreasing renal function.
Methods: Between 1999 and 2004, 125 consecutive patients underwent angiography and intervention for renal salvage
and formed the basis of this study. Inclusion criteria for this study included serum creatinine greater than 1.5 mg/dL,
ischemic nephropathy, and high-grade RAS perfusing a single functioning kidney. Patients undergoing PTA/S for
renovascular hypertension or fibromuscular dysplasia or in conjunction with endovascular stent grafting for aneurysm
repair were excluded. The original angiographic imaging was evaluated for lesion grade and parenchymal kidney size. All
medical records and noninvasive testing were reviewed. Preoperative and postoperative patient data were standardized
and analyzed by using 2 tests for nominal values and t tests for continuous variables. The Modification of Diet in Renal
Disease equation was used to estimate glomerular filtration rate (GFR), and univariate analysis was performed.
Results: Preoperative variables included the presence of coronary artery disease (93%), diabetes (44%), tobacco use (48%),
and hypercholesterolemia (70%). RAS was suspected on the basis of preoperative duplex imaging or magnetic resonance
angiography. Aortography and PTA/S were performed in 125 patients (mean age, 71 years; 59% male) with a mean
baseline creatinine level of 2.2 mg/dL. There were two mortalities (1.6%) in the 30-day postoperative period, but there
was no case of acute renal loss. Blood pressure decreased after PTA/S (151/79 mm Hg before vs 139/72 mm Hg after
1 month; P < .03). For all patients, the estimated GFR went from 33  12 mL · min1 · 1.73 m2 (mean  SD) to 37 
19mL · min1 · 1.73m2 at 6 months (P .10). Sixty-seven percent of treated patients had improvement (>10% increase in
GFR) or stabilization of renal function. A rapid decline in GFR before intervention was correlated with improvement
after PTA/S. Responders after PTA/S had a 27% decrease in GFR before intervention (44  13 mL · min1 · 1.73 m2
to 32  13 mL · min1 · 1.73 m2; P < .001) with a negative to positive slope change in GFR values. Ten patients
underwent reintervention for in-stent restenosis. Cases without improvement in GFR after PTA/S were associated with
eventual dialysis need (P  .01; mean follow-up, 19 months). Survival at 3 years was 76%, and dialysis-free survival was
63% as estimated by Kaplan-Meier analyses.
Conclusions: Renal artery stenoses causing renal dysfunction can be safely treated via endovascular means. Rapidly
decreasing renal function is associated with the response to renal artery angioplasty/stenting and helps identify patients
for renal salvage. (J Vasc Surg 2007;45:101-9.)Marked technical advances have been made in the
endovascular treatment of renal artery occlusive disease.
Despite these advances in renal artery intervention, the
selection of patients for medical therapy, endovascular ther-
apy, or surgical bypass remains controversial. This contro-
versy has been fueled by the largely equivocal results from
the three prospective, randomized trials1-3 comparing per-
cutaneous transluminal balloon angioplasty (PTA) with
medical therapy for renovascular hypertension. Despite the
documentation of a relatively safe procedure, balloon an-
gioplasty had only a modest effect on blood pressure in
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poorly controlled hypertension. A large fraction of cross-
overs in the Dutch Renal Artery Stenosis Intervention
(DRASTIC) trial and the lack of primary stenting may have
hampered these studies.4 Furthermore, the question of
whether renal intervention can improve or preserve renal
function remains unanswered because none of these indi-
vidual trials was designed to answer this question.
In addition to renovascular hypertension, RAS can lead
to progressive deterioration of renal function. The restora-
tion or preservation of renal function is termed renal salvage
and can be accomplished by revascularization in patients
with RAS causing renal insufficiency. Renovascular hyper-
tension may be overdiagnosed, but RAS causing renal
insufficiency and eventual renal loss may be underappreci-
ated and consequently undertreated.5,6 Unresolved con-
cerns in the treatment of renal insufficiency include patient
selection, periprocedural safety, and long-term renal func-
tion response and served as the impetus for this study.
The objective of this study was to review our experience
treating renal insufficiency secondary to RAS via endovas-
101
JOURNAL OF VASCULAR SURGERY
January 2007102 Kashyap et alcular means. Although treatment of RAS with PTA and
stenting (PTA/S) is now considered routine, the long-term
data and outcome data are limited. Preventing further renal
deterioration remains a clinical challenge in this patient
population, but it is a goal that has profound individual
patient and societal implications.
PATIENTS AND METHODS
Patient population. Between 1999 and 2004, 125
consecutive patients underwent angiography and interven-
tion for renal salvage. After institutional review board ap-
proval, the treatment of these patients formed the basis of
this retrospective study. All patients in this series had a
serum creatinine level greater than 1.5 mg/dL. Patients
with ischemic nephropathy with an acute decline in renal
function associated with volume overload or high-grade
RAS perfusing a single functioning kidney (Fig 1) and serum
creatinine greater than 1.5 mg/dL were also included in
this series. Patients undergoing PTA/S for purely renovas-
cular hypertension with creatinine less than 1.5 mg/dL, for
fibromuscular dysplasia, or in conjunction with endovascu-
lar stent grafting for aneurysm repair were excluded and
numbered approximately an additional 300 patients. All
clinical, perioperative, and demographic data were obtained
through review of original hospital and physician records,
including data collected prospectively in a departmental reg-
istry. The original angiographic, duplex ultrasonographic, and
computerized tomographic imaging was reviewed via cap-
tured and stored electronic images (MagicView 300 x-ray
program, Siemans AG, Germany). The original angio-
graphic imaging was evaluated for lesion grade and paren-
chymal kidney size.
Preoperative demographic data were obtained, includ-
ing sex, risk factors, and symptoms. Clinical factors in-
cluded presence of hypertension, diabetes mellitus, coro-
nary artery disease (CAD), hyperlipidemia, and tobacco
use. CAD was characterized as cases with no active disease
(low risk), optimized cardiac function (intermediate risk),
or active disease with angina or heart failure (high risk). For
tobacco use, both current and ex-smokers were included in
the analyses.
Procedural technique. Percutaneous interventions
were performed in dedicated endovascular suites with dig-
ital subtraction capability. Preprocedure intravenous hydra-
tion was used and continued after the procedure for 12 to
24 hours. N-Acetylcysteine (600 mg twice daily) was used
selectively in recent years. Access was obtained via the
femoral artery in 80% of cases, with brachial artery access
used preferentially in patients with a known severely
downsloping renal artery and ptotic kidney. For aortogra-
phy in the visceral aortic segment, both gadolinium (total
30 mL) and carbon dioxide were used as alternative contrast
agents in patients with creatinine greater than 2.5 mg/dL.
Renal artery pressure gradients were not routinely obtained
except in cases in which preoperative duplex, computed
tomographic, or magnetic resonance imaging indicated
high-grade lesions and was discrepant from angiographic
results. In general, a 6F system with a 0.014-inch stiffguidewire and primary stenting with a premounted balloon-
expandable stent in the 6.0- to 6.5-mm range was used. All
patients in recent years received clopidogrel, which was
continued for at least 3 months.
Follow-up clinical documentation included the resolu-
tion of hypertension or uremic symptoms and serum mark-
ers of renal function. The patency of the treated renal lesion
was evaluated by noninvasive vascular laboratory testing via
color-flow Doppler ultrasonography scheduled on a 3- to
Fig 1. A, A representative magnetic resonance angiography im-
age of a patient in this series. The right renal artery is occluded, and
the right kidney is atretic. The left kidney size is preserved, but
there is a high-grade proximal renal artery stenosis. The baseline
serum creatinine level was 2.0 mg/dL. The patient was treated
with primary stenting of the left renal artery stenosis, with improve-
ment of renal function and blood pressure control. B, A distal
protection device was used in this case and captured embolic
debris.6-month basis. Approximately 50% of the scheduled ultra-
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scanning was obtained in a few patients and also reviewed.
Patients with noninvasive studies indicating restenosis un-
derwent repeat angiography, pressure measurements, and
angioplasty or additional stent placement. The interval of
follow-up at the Cleveland Clinic Foundation was recorded
and averaged 19.4 months (range, 1-67 months).
Data analysis and statistical methods. Periprocedural
data, associated morbidity, and mortality within 30 days of
the procedure were determined. Patient data were stan-
dardized and analyzed. Serum creatinine was obtained at a
mean of 57% of outpatient visits (range 100% at the preop-
erative visit to 41% at 1 year after PTA/S). The Modifica-
tion of Diet in Renal Disease equation7 was used to esti-
mate the glomerular filtration rate (GFR), which is
expressed in milliliters per minute per 1.73 m2:
GFR 186 creatinine1.154 age0.203
 0.742 (if female) 1.210 (if black)
Individual GFR curves were reviewed, and patients
were characterized as responders, nonresponders or stabi-
lized after PTA/S. Responders were defined as patients
with at least a 10% improvement in GFR over the first
6 months. Nonresponders had a decrease in GFR at least
10% over the first 6 months, and stabilized patients had
GFR responses of 10% to 10% in that interval.
For comparative analyses of categorical measures, 2
tests were used, except where small cell sizes existed, when
Fisher exact tests were performed. For ordinal variables of
interest, Mantel-Haenszel methods were used, and for
continuous variables, two-sided t tests were performed.
When the three-level responder measure was com-
pared, similar procedures were performed, except that all
tests on categorical factors were Mantel-Haenszel proce-
dures because of the ordered nature of the responder
variable. Analysis of variance models were used to compare
the three groups on continuous measures. To measure the
survival rates for the entire cohort, Kaplan-Meier estimators
were used to estimate the survival function over time. All
tests were performed by using SAS software (version 9.1;
SAS Institute, Cary, NC) and used a .05 significance level.
RESULTS
A total of 125 patients underwent angiography and
PTA/S for renal insufficiency. Preoperative demographic
and clinical variables are listed in Table I. The mean age of
all patients was 71 years; most were male and had CAD and
hypercholesterolemia. Approximately one half of the pa-
tients had diabetes, and a similar percentage used tobacco.
The mean preoperative blood pressure for the group was
151/79 mm Hg (Table II). Other preoperative renal vari-
ables included a serum creatinine level of 2.2 mg/dL, an
estimated GFR of 33  12 mL · min1 · 1.73 m2, a
preserved renal size of 10.6 cm, and a mean RAS of 73%.
Angiography and PTA/S were performed in all 125
patients; 35 required bilateral intervention (9% staged), and
10 had RAS that was treated perfusing a single functioning
kidney. The procedures were performed with a high degreeof technical success. Six patients had a renal artery flow–
limiting dissection, all in the earlier years of this experience
when primary stenting was not routinely used. Four of
these cases had post-PTA dissection, which resolved with
stenting, and two cases resolved with prolonged balloon
inflation. There was no case of periprocedural acute renal
loss. Seven access-related complications occurred, includ-
ing femoral hematoma (n  3), femoral pseudoaneurysm
(n 2), and brachial artery injury (n 2). There were two
mortalities (1.6%) in the 30-day postoperative period. One
patient with known coronary disease died suddenly of a
cardiovascular event. The second patient died at an emer-
gency department at another institution of unclear causes.
Follow-up of these patients averaged 19.4 months,
with a range from 1 to 67 months (median, 15 months).
There was a significant decrease in the mean blood pressure
for patients in this series after PTA/S. Preoperative blood
pressure was 151  33 mm Hg systolic and 79  16 mm
Hg diastolic. Mean postoperative blood pressures obtained
in the first month were significantly lower, with systolic
pressures of 139  26 mm Hg and diastolic pressures of
72  16 mm Hg (P  .02 for systolic values; P  .03 for
diastolic values). Serum creatinine for all patients was 2.1
1.0 mg/dL at 6 months and 2.4  1.5 mg/dL at 1 year
after renal PTA/S. Figure 2 depicts the mean GFR values
for all patients from 4 months before surgery to 12 months
after surgery. Serum creatinine evaluation was scheduled
for all patients but was obtained in approximately 57% of
patients at each interval (range, 41%-100%). The absolute
Table I. Demographic and clinical factors for patients
undergoing percutaneous transluminal angioplasty and
stenting of renal arteries for renal salvage (n  125)
Variable Data
Mean age, y (range) 71 (43-87)
Male sex 74 (59%)
Black 8 (6%)
CAD 117 (93%)
Diabetes 56 (44%)
Tobacco use 61 (48%)
Hypercholesterolemia 88 (70%)
CAD, Coronary artery disease.
Data are number of patients (%) unless otherwise noted.
Table II. Preoperative renal factors (n  125)
Variable Data
Mean blood pressure (mm Hg)
Systolic 151  33
Diastolic 79  16
Serum creatinine (mg/dL) 2.2  0.9 (1.5-6.7)
GFR (mL · min1 · 1.73 m2) 33  12 (6.6-61.8)
Mean RAS (%; range) 73% (55%-99%)
Kidney size (cm) 10.6  1.4 (7-14.5)
GFR, Glomerular filtration rate; RAS, renal artery stenosis.
Data are represented as mean  SD (range).values of GFR do not change substantially over this inter-
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after intervention.
Patients were stratified as responders, stabilized, or
nonresponders after renal PTA/S (Fig 3). This was based
on review of individual GFR curves. Responders (n  53)
had a steep decline in GFR before PTA/S. The mean GFR
value 4 months before intervention was 44  13 mL ·
min1 · 1.73 m2 (mean  SD), which decreased to 39
17 mL · min1 · 1.73 m2 1 month before the procedure.
Kidney function further declined to 32  13 mL · min1 ·
1.73 m2 immediately before PTA/S (P  .001; t test;
time4 months vs time 0). This represented a decrease in
GFR of 3 mL · min1 · 1.73 m2 per month. Similarly,
patients who had a stabilization of their kidney function
(n  31) after surgery had a declining preintervention
GFR slope. Their GFR values mirrored the responders’
values (42  16, 37  9, and 34  9 mL · min1 · 1.73
m2; P  .03). Nonresponders (n  41), however, had
a depressed kidney function that remained fairly constant
before surgery. Their GFR values 4 months, 1 month,
and immediately before PTA/S were 36  17, 32  11,
and 34  11 mL · min1 · 1.73 m2, respectively (P 
.53).
Univariate analyses of demographic variables and risk
factors and their association with response to PTA/S were
performed in an attempt to find preoperative variables that
may be associated with improved outcomes after interven-
tion. When responders were compared with nonre-
sponders, no preoperative clinical or demographic factor
was associated with improvement in GFR after PTA/S
for renal salvage (Tables III and IV). Nonresponders had
a higher frequency of diabetes (54%) when compared
with responders (40%), but this was not statistically
significant (P  .18). It is important to note that neither
Fig 2. Mean estimated glomerular filtration rate (SE) for all
patients undergoing percutaneous transluminal angioplasty and
stenting (n  125). The y-axis represents months, with time 0
representing the renal intervention. At each interval, serum creat-
inine levels were obtained in approximately 57% of patients (range,
41%-100%; n  64 at –4 months; n  77 at 1 month; n  125
at intervention; n 69 at 1 month; n 53 at 3 months; n 63 at
6 months; n  51 at 12 months).male sex nor ethnic background nor preoperative serumcreatinine levels was associated with response after
PTA/S. Patients with preoperative serum creatinine less
than 2.0 mg/dL had similar frequencies in the responder
(49%) and nonresponder (56%) groups (P  .5). Also,
the preoperative finding of bilateral RAS or unilateral
RAS with a single functioning kidney leading to renal
PTA/S was not associated with response after treatment
(P  .9).
Univariate analyses were also conducted by combining
the responder and stabilized data vs the nonresponder data.
Patients dichotomized to either worsening GFR before
surgery (n 57) or same (n 33)/increasing (n 9) GFR
before surgery were significantly different. The frequency of
worsening preoperative GFR was 71% in responders/stabi-
lized patients but only 29% in nonresponders (P .001).
The durability of the initial PTA/S was reviewed. Ten
patients required reintervention for renal artery restenoses
identified by follow-up duplex ultrasound testing. These
patients underwent 13 procedures (3 patients underwent
tertiary intervention) with PTA alone or additional stenting
of nonostial lesions. One patient in this group of 10 pro-
gressed to dialysis 14 months after her initial procedure for
renal salvage.
Outcome beyond 1 year was assessed for these 125
patients. Late mortality after PTA/S for renal salvage
occurred in 26 patients at a mean of 22 months after the
procedure (Table V). Most patients died as a result of
cardiovascular causes even though the documented myo-
cardial infarction rate was low. Seventeen patients re-
quired renal replacement therapy with dialysis. Four of
the 53 patients with an initial response to PTA/S went
on to dialysis at a mean of 17 months after the procedure.
Eleven (36%) of 31 patients with available follow-up who
did not respond to PTA/S went on to dialysis. Nonre-
sponders were significantly more likely to have an even-
tual dialysis need (P  .01). Freedom from dialysis in
Fig 3. Glomerular filtration rate (GFR) in patients stratified by
response to intervention. Negative months represent the preoper-
ative time frame for all patients. Patients who responded or stabi-
lized after intervention had significant decreases in GFR before the
intervention (P  .01), whereas nonresponders had no significant
change.survivors was estimated by using Kaplan-Meier analyses.
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respectively. Nonresponders had lower rates of 92% and
62% at the same intervals (P  .095; log-rank test).
Table III. Frequencies and percentages of preoperative m
Variable Total
Res
n
Sex
Male 62 36
Female 32 17
Ethnicity
Black 7 3
White 87 50
Diabetes
No 51 32
Yes 43 21
Hypercholesterolemia
No 31 18
Yes 63 35
Tobacco use
No 52 28
Yes 42 25
CAD
Low risk 20 15
Intermediate 62 30
Angina/heart failure 12 8
CAD, Coronary artery disease.
P values are from 2 tests, except where the Fisher exact test (F)was used as a
the levels were ordinal.
Table IV. Means and standard deviations for preoperative
Variable Responders (n 
Age (y) 70.3  8.7
Preoperative SBP* (mm Hg) 158  35
Preoperative DBP* (mm Hg) 82  19
Preoperative creatinine (mg/dL) 2.4  1.2
SBP, Systolic blood pressure; DBP, diastolic blood pressure.
P values are from t tests.
*Data available on 52 patients.
Table V. Postoperative measures and outcome by glomer
Factor Total
Responder
n %
30-d mortality
No 120 50 98.0
Yes 2 1 2.0
Late death
No 70 30 71.4
Yes 26 12 28.6
Myocardial infarction
No 80 33 94.3
Yes 4 2 5.7
Dialysis
No 72 33 89.2
Yes 17 4 10.8
P values are from Mantel-Haenszel tests.Estimates of long-term survival and dialysis-free survivalusing Kaplan-Meier analyses were also performed (Fig
4). Overall survival was 88% at 1 year, 85% at 2 years, and
76% at 3 years. Dialysis-free survival was slightly lower,
res by glomerular filtration rate responder status
r Nonresponder
P
value% n %
.65
67.9 26 63.4
32.1 15 36.6
.70 (F)
5.7 4 9.8
94.3 37 90.2
.18
60.4 19 46.3
39.6 22 53.7
.82
34.0 13 31.7
66.0 28 68.3
.58
52.8 24 58.5
47.2 17 41.5
.37 (M)
28.3 5 12.2
56.6 32 78.1
15.1 4 9.8
f small sample size or where theMantel-Haenszel test (M)was used because
sures by glomerular filtration rate responder status
Nonresponders (n  41) P value
70.6  9.2 .84
144  29 .14
76  9 .15
2.2  0.8 .22
filtration rate responder status
Stabilized Nonresponder
P valuen % n %
.89
30 100 40 97.6
0 0.0 1 2.4
.79
17 73.9 23 74.2
6 26.1 8 25.8
.82
22 100 25 92.6
0 0.0 2 7.4
.010
20 90.9 19 63.3
2 9.1 11 36.7easu
ponde
result omea
53)ularwith rates of 85%, 77%, and 63% at the same intervals.
% an
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Chronic kidney disease affects 11% of the adult popu-
lation in the United States, and nearly 400,000 patients
have end-stage renal failure. Themorbidity andmortality of
end-stage renal disease are staggering, with a crude annual
mortality of 22% in the United States.8 Even lesser degrees
of chronic kidney disease can have significant consequences, as
observed in a recent population-based study of more than 1
million adults in which longitudinal GFR was assessed and
correlated with outcome.9 The risk of death increased as
GFR decreased below 60 mL · min1 · 1.73 m2. Further-
more, reduced GFR was independently associated with
cardiovascular events and hospitalization, with adjusted
hazard ratios greater than 3 for severe renal impairment
(30 mL · min1 · 1.73 m2). Halting the progression of
renal deterioration can have significant medical, societal,
and economic implications. Tremendous progress is being
made in targeted medical therapies for chronic kidney
disease in addition to blood pressure control and renin-
angiotensin blockade.5 However, a significant fraction of
patients receiving hemodialysis have renal vascular disease;
this indicates that RAS may be an underappreciated com-
ponent of renal failure.6 Thus, treatment of RAS via endo-
vascular meansmay play a role in amultifaceted approach to
halting the progression of renal dysfunction and renal loss.
RAS is a common finding and one that can either be
associated with devastating renal and systemic effects or
remain clinically silent. Our current limitations include the
ability to adequately assess the contribution of RAS to renal
function decline and the status of the renal parenchyma.
The natural history of RAS is progressive narrowing of the
inflow artery to the functioning renal mass. With continued
Doppler follow-up, renal arteries with significant stenoses
Fig 4. Kaplan-Meier estimates of long-term survival an
3 years, respectively, whereas dialysis-free survival was 85(60%) have approximately a 20% progression of diseaseper year, with 11% progressing to renal occlusion within
2 years.10
Surgical revascularization for retrieval of renal function
can be accomplished, with documented durable long-term
results in centers of excellence with a dedicated interest in
renovascular surgery.11,12 By and large, endovascular ther-
apy has supplanted open renal reconstruction in the United
States13 secondary to the perceived lower morbidity and
mortality by referring physicians and patients. The endo-
vascular treatment of renal artery occlusive disease has
evolved with significant strides in the design and delivery of
both angioplasty balloons and stents to allow safe, percuta-
neous revascularization of renal blood flow. Many of the
technical advances revolve around lower-profile devices on
a 0.014-inch platform, rapid exchange systems, and ad-
vances in anticoagulation and antiplatelet agents. Further-
more, there remains a possibility of improving patency by
decreasing restenosis with drug-eluting stents and decreas-
ing end-organ embolization by using distal protection de-
vices.
We studied the outcome of 125 consecutive patients
with renal insufficiency who underwent endovascular man-
agement of renal atherosclerotic disease. Our results indi-
cate that PTA/S can be accomplished with low morbidity
and mortality, despite the presence of significant comor-
bidities in this cohort. The baseline serum creatinine in this
group was 2.2 mg/dL, with an estimated GFR of 33 mL ·
min1 · 1.73 m2. The clinical grouping of renal insuf-
ficiency, hypertension, noninvasive imaging indicating
high-grade renal stenoses, and preserved renal size
(mean, 10.6 cm) prompted intervention in this series. The
preoperative indication for all 125 patients was renal sal-
vage. Ten patients had a stenotic renal artery supplying a
ysis-free survival. Survival was 88% and 76% at 1 and
d 63% for the same intervals.d dialsingle functioning kidney. An additional 69 patients were
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magnetic resonance angiography imaging. However, at the
time of angiography, 35 of these 69 had compelling bilat-
eral disease necessitating intervention. The remaining 46
patients had unilateral disease and escalating serum creati-
nine, suggesting worsening renal function.
Despite clinical variables indicating renal insufficiency
secondary to RAS, one third of patients undergoing inter-
vention did not respond and had continued decline in renal
function. This underscores our current limitation in pre-
dicting renal function recovery after renal artery PTA/S.
These nonresponses were, as expected, associated with the
eventual need for dialysis. Patients who had improvement
or stabilization in renal function after PTA/S had an asso-
ciated rapid decrease in GFR before surgery. This under-
scores the importance of the calculation of estimated GFR.
Serum creatinine is a commonly obtained laboratory test
and is included in many routine metabolic panels. How-
ever, creatinine is altered by many factors, including muscle
mass, which diminishes with age. Thus, estimation of GFR
can be a more sensitive marker of renal function and can aid
in identifying patients with progressive deterioration in
renal function.
Previous studies have evaluated renal function after
PTA/S by using serum creatinine. One of the first studies
to evaluate change in renal function after renal stenting was
performed in the United Kingdom by Harden et al14 in
1997. Thirty-two patients with atherosclerotic disease were
treated with PTA/S, and 23 had sufficient long-term data
for analysis. Overall, 34% of patients improved, 34% stabi-
lized, and 28% worsened in their experience. Using a least-
squares method of the reciprocal serum creatinine plotted
over time, the authors found that the rate of renal deterio-
ration was improved in 78% of patients. The importance of
the trajectory of renal function decline and its association
with response to intervention have been previously ob-
served. Beutler et al15 prospectively evaluated 63 patients
with ostial RAS and renal insufficiency. Preintervention
renal function was stable in 28 patients and declining in 35,
defined as a greater than 20% increase in serum creatinine in
the previous 12 months. At the 12-month follow-up, pa-
tients with declining preintervention renal function had a
reversal of their kidney function, with stabilization or im-
provement in serum creatinine. This observation has been
corroborated in other nonrandomized studies by using the
slope change in reciprocal serum creatinine.16,17 These
studies support the concept that acute changes in renal
function may represent ischemic damage with retrievable
renal mass. However, chronically low renal function with
slow progression may represent irreversible parenchymal
damage.
In a recent article, Zeller et al18 evaluated renal func-
tion after PTA/S in 215 patients in a prospective study.
Serum creatinine and mean arterial blood pressures served
as the primary end points for analysis, and the authors
observed a mild decrease in both creatinine and blood
pressure in 52% of patients available for 1-year follow-up.
Despite a modest improvement in median serum creatininefor all patients (1.21 to 1.10 mg/dL; P  .047), the
authors found a greater improvement in patients with
higher preintervention baseline creatinine (1.5 mg/dL).
The importance of renal function changes after PTA/S is
highlighted by a recent study.19 In 261 patients undergo-
ing intervention, patients with improved renal function
after stenting had significantly longer survival than patients
without improved renal function. Taken together, our re-
sults and previous studies indicate that in selected patients,
PTA/S slows or reverses the progression of renal failure.
Patients with a recent progressive loss of renal function may
be the most likely to have a favorable outcome.
The technical details of the performance of PTA/Smay
be relevant in the prevention of acute complications. We
speculate that intravenous hydration; a liberal posture re-
garding the use of nonnephrotoxic contrast agents for
aortography, including gadolinium and carbon dioxide;
and the use of a distal protection device may have benefit.
The use of a distal protection device during renal interven-
tion makes intuitive sense given the capture of embolic
debris in a significant fraction of cases.20,21 Additional
evidence that atheroembolic material could cause renal
parenchymal damage has been obtained via an ex vivo study
using human arterial plaque specimens.22 Currently, the
outcome of renal PTA/S with a distal protection device
is being evaluated in the National Institutes of Health–
supported randomized controlled Cardiovascular Outcomes
in Renal Atherosclerotic Lesions (CORAL) trial.23
The limitations of our study are worthy of mention.
The preoperative indication for all patients was renal sal-
vage on the basis of clinical, biochemical, and noninvasive
imaging data, including duplex scan or magnetic resonance
angiography. However, at the time of angiography, ap-
proximately half of the patients thought to have bilateral
RAS had compelling bilateral disease necessitating inter-
vention. This was a retrospective study in a referral center
where many of the patients were from out of state; this
made consistent follow-up extremely difficult. Nineteen
patients returned for a single follow-up visit. Nevertheless,
96 patients (77%) had longer-term follow-up data available.
Clinical testing was not standardized and was left to the
discretion of the treating physician. Thus, all patients did
not have routine serum chemistries, duplex scans, or other
noninvasive imaging studies at follow-up, and this may
have led to an underestimation of restenosis of treated renal
arteries.
In summary, the treatment of RAS for renal salvage can
be accomplished via endovascular means with low morbid-
ity or risk of renal loss. In our experience, the most marked
benefit is accomplished in patients with rapidly deteriorat-
ing renal function before renal PTA/S. Whether this strat-
egy of treatment is superior to medical therapy and the risk
of RAS progression, kidney atrophy and attendant cardio-
vascular complications can be answered only in a random-
ized trial. Until further information is available, the keys to
success in the endovascular treatment of RAS include care-
ful patient selection, preoperative preparation in patients
JOURNAL OF VASCULAR SURGERY
January 2007108 Invited Commentarywith compromised renal function, and meticulous tech-
nique in the performance of the procedure.
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The article by Kashyap et al helps define outcomes for renal
intervention in the presence of renal insufficiency, a cohort previ-
ously defined as high risk for surgical therapy. Hallett et al1
evaluated 402 patients having surgical renal revascularization with
preoperative serum creatinine values 2 mg/dL. Perioperative
mortality was 15%, and a substantial number went on to hemodi-
alysis, including nearly one third of patients whose baseline serum
creatinine was 3 mg/dL.
The current data provide a baseline for expected results afterdata for surgical repair), but they also raise a number of questions.
Why did renal function not improve more after intervention?
Although many patients did respond, mean serum creatinine was
2.2 mg/dL at baseline and 2.4 mg/dL at 1 year; clearly these
patients, in general, continued to have deteriorating renal function
over time that was not halted by endovascular intervention.
Although the authors define success as either stabilization or
improvement (which seems entirely reasonable), when looked at in
another light, 72 (58%) of 125 patients did not improve—they
were not responders—a sobering statistic. Rapid decline in renal
